Category
Page
About us - PM Group
ATMP facilities are different to the more conventional pharma facilities, often requiring heightened segregation when compared to other modalities.
Alf Penfold, PM Group’s GMP and Regulatory Technical Director, explains more ahead of this year’s ISPE UK Affiliate Conference and Awards.
“Many organisations are evaluating how different modalities may be combined within the same facility. This may be as a result of having acquired a building, or having constructed an agnostic building”, said Alf.
“Therefore, being able to accommodate multiple modalities within the same facility is becoming increasingly important. There are a number of aspects to consider to safely achieve this. We have developed an industry leading approach for risk assessing mixed modality manufacturing scenarios. This is a proven approach, successfully applied for a range of very different modalities. Our approach links escalating facility design features with risks associated with combining different modalities,” added Alf.
Alf will be presenting on PM Group’s multi-modality approach at this year’s ISPE UK Affiliate Annual Conference. He will also be joined by PM Group's Biologics and Advanced Therapies SME, Tom Bannon.
Read more about Mixed Modality Manufacturing
Learn more here about the ISPE UK Affiliate Annual Event, where PM Group are proud to be platinum sponsors, on 21st November 2024.